Sergio Traversa - 12 Dec 2025 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: RLMD
Reported as of: 12 Dec 2025
Net transaction value: +$113,300
SEC form: 4
Accepted by SEC: 16 Dec 2025, 09:30:49 UTC
Prior SEC filing: 06 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Sergio Traversa

Key filing fact

Sergio Traversa filed Form 4 for RELMADA THERAPEUTICS, INC. (RLMD) on 16 Dec 2025.

Key facts

This page summarizes Sergio Traversa's Form 4 filing for RELMADA THERAPEUTICS, INC. (RLMD).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Dec 2025, 09:30.

Change

Previous filing in this sequence was filed on 06 Nov 2025.
Current net transaction value: +$113,300.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001565832 Primary reporting owner

TRAVERSA SERGIO

Relationship: Chief Executive Officer, Director
Address: C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES
Signature: /s/ Sergio Traversa
Signature date: 16 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RLMD transaction

Common Stock

Purchase

Transaction value: $113,300
Shares: +27,500
Change %: +2.2%
Price: $4.12
Shares after: 1,300,000
Date: 15 Dec 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RLMD transaction Derivative

Stock Appreciation Rights

Award

Transaction value: $0
Shares: +1,198,000
Change %
Price: $0.000000
Shares after: 1,198,000
Date: 12 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,198,000
Exercise price: $4.06
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

Footnote F2

Purchase prices range from $4.10 to $4.12 per share, inclusive.

Footnote F3

The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.